Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ozone gel plus sound waves could soothe stubborn shoulder pain

NCT ID NCT07316738

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether applying an ozonated gel with ultrasound (phonophoresis) can reduce pain and improve shoulder function in people with chronic supraspinatus tendinitis. Forty adults aged 30-60 with mild to moderate tendon issues will receive either the ozone gel treatment or standard care (heat and exercises) for four weeks. Researchers will measure pain, range of motion, and disability before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ozonated gel
What this could lead to
If it works, this could offer a new, non-invasive way to ease shoulder pain and improve movement for people with chronic tendinitis.
What could go wrong
This is a small, early-stage trial with only 40 people. The treatment may not prove more effective than standard care, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients from 30-60 years old from both genders. * The patients will be assigned to the study will be diagnosed with grade I or II supraspinatus tendinitis based on Neer's classification. * The patients suffered from supraspinatus tendinitis for more than 3 months and taking non-steroidal anti-inflammatory drugs suggested by orthopedist. * All patients have body mass index between 18.5 and 29.9 kg/m2. Exclusion Criteria: * Grades III of supraspinatus tendinitis. (Bone spurs and tendon rapture) * Any past shoulder surgical interventions. (Rotator cuff repair, labrum tear and open reduction internal fixation) * Shoulder joint instability * Shoulder fracture. * Non-cooperative subjects. * Neuromuscular diseases (spinal muscular atrophy, whiplash injury) * Cardiovascular disease. * History of cancer. * Systemic diseases such as rheumatoid arthritis, Reiter's syndrome, or diabetes. * Severe medical and neurological or psychiatric disorders. * Pregnant and lactating women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Supraspinatus tendinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tendinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Supraspinatus tendinitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AL-Nasaem outpatient clinic

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.